[ij] [ij] [ij] 
Email id

Year : 2021, Volume : 14, Issue : 3
First page : ( 1811) Last page : ( 1814)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2021.00321.8

Emergent strategy in management of inflammatory bowel disease: A narrowed in on novel drugs

Chandra Srikanta1, Das Avik2, Roy Tathagata3*, Bose Preeta3, Paul Susanta3, Mukherjee Lucky4, Das Arijit5

1Assistant Professor, Jakir Hossain Institute of Pharmacy, Department of Pharmacology, Raghunathganj, Murshidabad, 742225

2Assistant Professor, Gupta College of Technological Sciences, Department of Pharmacology, Asansol, West Burdwan, West Bengal, 713301

3Department of Pharmaceutical Technology, JIS University, Kolkata-700109

4Assistant Professor, Sister Nivedita University, Kolkata

5Assistant Professor, Bharat Technology, Uluberia, Howrah

*Corresponding Author E-mail: troy@jisuniversity.ac.in

Online published on 30 April, 2021.


Inflammatory bowel disease is looming large on the modern society which has raised the brows of the medical scientists in both the developed and developing countries. According to American Gastrological Society (AGS) IBD is defined acute or chronic idiopathic ulceroinflammatory condition of the bowel which may or may not have transmural stretch. IBD encompasses two pivotal kinds of pathological condition Ulcerative colitis (UC) and Crohn's disease (CD). Epidemiologically UC has a greater prevalence in the global prospective. So we decided to zero in on UC in our work ahead. Pivotal contours may be featured as toxic megacolon, pseudopolyps and backwash ileitis. The featured encountered in the clinical course of the disease are multiferrous spanning from rectal bleeding, abdominal pain, weight loss and malasei. Coming to the option available for management they include both non pharmacological approach and pharmacological approach. Under the nonpharmacological approach life style changes like monitored dieting, exercise may plays a pivotal role and psychological intervention also deployed to control the functional aspects of the disease. On the other hand Salfasalazine and Mesalamine are still considered as a corner stone of the therapy as per as pharmacological approach.



Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease, Sulfasalazine, Mesalamine.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
690,201,159 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.